ID   MOLM-13/AZA
AC   CVCL_C0WJ
DR   Wikidata; Q114312311
RX   PubMed=33669837;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C3247; Myelodysplastic syndrome
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2119 ! MOLM-13
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 29-06-23; Version: 4
//
RX   PubMed=33669837; DOI=10.3390/ijms22042076;
RA   Janotka L., Messingerova L., Simonicova K., Kavcova H., Elefantova K.,
RA   Sulova Z., Breier A.;
RT   "Changes in apoptotic pathways in MOLM-13 cell lines after induction
RT   of resistance to hypomethylating agents.";
RL   Int. J. Mol. Sci. 22:2076.1-2076.24(2021).
//